Q1 2025 EPS Estimates for Integer Holdings Co. Cut by Zacks Research (NYSE:ITGR)

Integer Holdings Co. (NYSE:ITGR) – Research analysts at Zacks Research dropped their Q1 2025 earnings estimates for Integer in a report issued on Thursday, April 18th. Zacks Research analyst D. Dey now expects that the medical equipment provider will post earnings per share of $1.42 for the quarter, down from their prior forecast of $1.44. The consensus estimate for Integer’s current full-year earnings is $5.31 per share. Zacks Research also issued estimates for Integer’s Q2 2025 earnings at $1.41 EPS.

Other analysts have also recently issued reports about the stock. Benchmark upped their price objective on shares of Integer from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, March 28th. CL King started coverage on Integer in a report on Thursday, March 14th. They set a “buy” rating and a $137.00 price target for the company. Bank of America raised Integer from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $105.00 to $135.00 in a research note on Monday, April 15th. Finally, KeyCorp raised their target price on Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research note on Tuesday, April 9th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Integer has an average rating of “Moderate Buy” and a consensus price target of $120.50.

Integer Trading Up 0.0 %

Shares of Integer stock opened at $116.65 on Monday. Integer has a 12-month low of $69.40 and a 12-month high of $121.53. The stock has a market capitalization of $3.91 billion, a P/E ratio of 43.36, a price-to-earnings-growth ratio of 1.61 and a beta of 1.10. The company has a 50-day simple moving average of $112.03 and a 200 day simple moving average of $99.05. The company has a quick ratio of 1.71, a current ratio of 2.80 and a debt-to-equity ratio of 0.64.

Integer (NYSE:ITGR) last posted its earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 EPS for the quarter, topping the consensus estimate of $1.34 by $0.05. Integer had a return on equity of 10.80% and a net margin of 5.68%. The business had revenue of $413.15 million during the quarter, compared to the consensus estimate of $409.04 million. During the same quarter last year, the company earned $1.11 EPS. Integer’s revenue was up 10.9% on a year-over-year basis.

Institutional Trading of Integer

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Blue Trust Inc. grew its position in shares of Integer by 483.3% during the 4th quarter. Blue Trust Inc. now owns 455 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 377 shares during the period. Principal Securities Inc. acquired a new stake in Integer during the 4th quarter worth $67,000. Emerald Mutual Fund Advisers Trust raised its position in shares of Integer by 66.6% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,461 shares of the medical equipment provider’s stock valued at $115,000 after acquiring an additional 584 shares during the last quarter. Van ECK Associates Corp lifted its stake in shares of Integer by 22.0% in the 3rd quarter. Van ECK Associates Corp now owns 1,733 shares of the medical equipment provider’s stock valued at $136,000 after purchasing an additional 313 shares during the period. Finally, Quadrant Capital Group LLC boosted its position in shares of Integer by 10.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,427 shares of the medical equipment provider’s stock worth $141,000 after purchasing an additional 132 shares during the last quarter. 99.29% of the stock is owned by institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.